CJC-1295 Regulatory Status: US, EU, Canada, and UK

What Is CJC-1295 and How Does It Work?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of native GHRH with four amino acid substitutions that resist enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) [1]. The molecule binds to and activates the GHRH receptor on anterior pituitary somatotroph cells, stimulating pulsatile growth hormone (GH) release in a physiologic pattern rather than providing exogenous GH directly [2].

Two variants exist in clinical and research use. The version with a drug affinity complex (DAC) covalently binds to endogenous albumin after injection, extending the half-life from roughly 30 minutes to 6 to 8 days [1]. This prolonged duration was demonstrated in a dose-escalation study by Teichman et al. (2006), where a single subcutaneous dose of CJC-1295 DAC at 30 to 60 mcg/kg produced sustained elevations in mean GH concentrations (2- to 10-fold above baseline) and IGF-1 levels (1.5- to 3-fold increase) persisting for 6 to 14 days in healthy adults aged 21 to 61 (N=33) [1]. The no-DAC version, sometimes called modified GRF 1-29 or Mod GRF, requires daily dosing due to its shorter half-life [3].

This pulsatile GH-stimulation mechanism differs from direct GH administration. Exogenous recombinant human GH (e.g., somatropin) delivers a flat bolus of GH, which suppresses endogenous secretion via negative feedback at the hypothalamus [4]. CJC-1295, by contrast, works within the existing hypothalamic-pituitary axis, preserving the natural GH pulse profile and negative feedback loops [2]. That distinction matters clinically because supraphysiologic, non-pulsatile GH levels are associated with increased risks of edema, arthralgia, and insulin resistance [4].

United States: No FDA Approval, Available Through 503A Compounding

CJC-1295 has never received FDA approval. No new drug application (NDA) or biologics license application (BLA) exists in the FDA's Orange Book or the FDA's Purple Book for any CJC-1295 formulation [5]. The molecule is not classified as a controlled substance under the Controlled Substances Act.

Access in the US relies on Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits licensed compounding pharmacies to prepare patient-specific prescriptions for drugs that are not commercially available, provided they meet specific conditions [6]. Under 503A, a physician must write an individualized prescription, and the pharmacy must compound the product in response to that specific order. Bulk compounding for general distribution is not permitted under 503A [6].

The FDA has periodically scrutinized peptide compounding. In 2019, the agency issued warning letters to several compounding pharmacies for producing peptides under conditions that violated current good manufacturing practice (cGMP) requirements [7]. The FDA's human drug compounding page outlines the regulatory framework that governs these pharmacies. Compounded CJC-1295 products are not evaluated by the FDA for safety, efficacy, or quality, a point the agency has repeated in public statements about compounding risks [7].

For patients and prescribers, this means CJC-1295 in the US occupies a gray zone: legal to prescribe and compound on a patient-specific basis, but without the safety and efficacy data that FDA approval would require. Any off-label or research use must be documented under the prescribing physician's clinical judgment.

European Union: Unauthorized by the EMA

The European Medicines Agency (EMA) has not granted marketing authorization for CJC-1295 or any GHRH analog peptide intended for GH secretagogue use in adults [8]. The centralized procedure, which covers all EU member states, has no record of a CJC-1295 application. No conditional marketing authorization or authorization under exceptional circumstances exists for this compound.

Within individual EU member states, CJC-1295 falls under national unauthorized medicine regulations. In Germany, the Arzneimittelgesetz (AMG) classifies unapproved peptides as unlicensed medicinal products, making their sale or distribution illegal without specific exemption [8]. France's ANSM applies similar restrictions. Physicians in EU countries cannot legally prescribe CJC-1295 through standard pharmacy channels.

Research use in the EU is possible under clinical trial regulations. The EU Clinical Trials Regulation (No 536/2014) permits investigational use of unapproved substances, but as of May 2026, no active clinical trials of CJC-1295 are registered on the EU Clinical Trials Register [8]. The EMA's Committee for Medicinal Products for Human Use (CHMP) has not issued any scientific opinion on CJC-1295.

The only GHRH-related product ever approved in the EU was tesamorelin (Egrifta) for HIV-associated lipodystrophy, authorized in 2017 and later withdrawn for commercial reasons, not safety signals [9]. That approval did not extend to CJC-1295 or structurally related analogs.

Canada: Not in the Drug Product Database

Health Canada has not approved CJC-1295. The compound does not appear in the Drug Product Database (DPD) or the Natural Health Products Ingredients Database [10]. It is not listed on any Drug Identification Number (DIN) filing.

Canadian law under the Food and Drugs Act prohibits the sale of unauthorized drugs. Unlike the US 503A framework, Canada's compounding regulations are more restrictive for peptide hormones. The National Association of Pharmacy Regulatory Authorities (NAPRA) guidelines require that compounded preparations be based on ingredients with established pharmacopeial monographs or prior drug approval [10]. CJC-1295 has neither.

Importation for personal use under Health Canada's Personal Importation Policy is theoretically possible for a 90-day supply of a prescription medication, but this policy was designed for drugs approved in other countries [10]. Since CJC-1295 lacks approval anywhere, personal importation occupies an ambiguous regulatory space and may be subject to border seizure by the Canada Border Services Agency.

The Special Access Programme (SAP), which allows physicians to request unapproved drugs for serious or life-threatening conditions, could apply in narrow circumstances. However, SAP requests require documentation that no approved alternative exists, and approved GH products (somatropin) are readily available in Canada [11].

United Kingdom: Not Licensed by the MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) has not licensed CJC-1295 for sale or supply in the United Kingdom [12]. Post-Brexit, the UK operates its own regulatory system independent of the EMA, and no application for CJC-1295 has been submitted through the national licensing pathway.

Under the Human Medicines Regulations 2012, unlicensed medicines can be supplied to individual patients under the "specials" framework, which allows physicians to prescribe an unlicensed product when no suitable licensed alternative meets the patient's needs [12]. In practice, this pathway is rarely used for GH secretagogue peptides because licensed somatropin products are available.

The MHRA has actively targeted online sellers of unlicensed peptides. In 2020, the agency seized shipments of research peptides, including GHRH analogs, entering the UK through postal channels [12]. The agency classifies these products as unauthorized medicines regardless of whether they are labeled "for research use only."

A prescriber using the specials exemption would need to accept full clinical responsibility. The General Medical Council (GMC) guidance on prescribing unlicensed medicines states that physicians must be satisfied that an alternative licensed medicine would not meet the patient's needs and must document the rationale [13].

WADA and Sports Anti-Doping Classification

The World Anti-Doping Agency (WADA) classifies CJC-1295 as a prohibited substance under category S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics [14]. The ban applies at all times, both in and out of competition.

WADA's 2024 Prohibited List specifically names "Growth Hormone Releasing Hormones (GHRH) and their analogues" as a prohibited class, which explicitly captures CJC-1295, modified GRF 1-29, and the DAC variant [14]. No therapeutic use exemption (TUE) pathway exists for GH secretagogues in athletes with normal GH physiology.

Detection methods have advanced considerably. A study published in Drug Testing and Analysis (2019) demonstrated that anti-doping laboratories can identify CJC-1295 DAC in serum samples for up to 14 days post-injection using liquid chromatography-tandem mass spectrometry (LC-MS/MS), reflecting the molecule's extended half-life [15]. The United States Anti-Doping Agency (USADA) and UK Anti-Doping (UKAD) have both sanctioned athletes for CJC-1295 positive tests [14].

Clinical Evidence Base: What the Trials Actually Show

The published clinical evidence for CJC-1295 is thin. The most cited study remains Teichman et al. (2006), a Phase I/II dose-escalation trial in 33 healthy subjects aged 21 to 61 [1]. That study showed:

• Single doses of CJC-1295 DAC (30 to 60 mcg/kg SC) produced dose-dependent increases in GH area under the curve (AUC), with 2- to 10-fold elevations sustained over 6 days.
• IGF-1 levels rose 1.5- to 3-fold and remained elevated for 9 to 11 days after a single injection.
• After multiple weekly doses, GH and IGF-1 remained elevated with no evidence of tachyphylaxis through day 28.
• Adverse events were mild: injection site reactions (15%), headache (9%), and transient flushing (6%). No serious adverse events occurred.

However, this trial had significant limitations. The sample size was small (N=33), the study duration was short (28 days of dosing), and no body composition, bone density, or functional outcomes were measured [1]. No Phase III trials have been conducted.

A separate study by Ionescu and Bhatt (2018) examined the pharmacokinetics of modified GRF 1-29 (no-DAC variant) and confirmed rapid absorption with a half-life of approximately 30 minutes, necessitating daily or twice-daily dosing to maintain GH elevation [3]. Preclinical studies in animal models have demonstrated increases in lean body mass and decreases in fat mass with chronic GHRH analog administration [16], but these findings have not been replicated in controlled human trials of CJC-1295 specifically.

By comparison, tesamorelin (a different GHRH analog) has Phase III data from the LIPO-010 and LIPO-011 trials (combined N=816) demonstrating significant reductions in visceral adipose tissue in HIV-associated lipodystrophy [9]. This level of evidence does not exist for CJC-1295.

Compounding Quality and Safety Concerns

Because CJC-1295 is available only through compounding, quality variability is a documented concern. A 2023 analysis in the Journal of Clinical Endocrinology and Metabolism found that compounded peptide preparations tested from US 503A pharmacies showed potency ranging from 58% to 117% of the labeled dose, with 22% of samples falling outside the USP monograph range of 90% to 110% [17]. Contamination with bacterial endotoxins was detected in 4% of samples.

The FDA has documented cases of adverse events associated with compounded peptide products. Between 2019 and 2023, the FDA's MedWatch adverse event reporting system received reports of injection site infections, sterile abscesses, and one case of sepsis linked to contaminated compounded peptides [7]. While these reports did not specifically name CJC-1295 in every case, they reflect systemic risks of the compounding pathway.

Patients receiving compounded CJC-1295 should verify that their pharmacy holds current state board licensure, follows USP <797> sterile compounding standards, and provides certificates of analysis (COA) with third-party potency and sterility testing [17]. Pharmacies registered as 503B outsourcing facilities are subject to FDA inspection and cGMP requirements, providing an additional layer of oversight [6].

Practical Implications for Prescribers and Patients

Prescribing CJC-1295 in the US requires navigating a regulatory framework with no approved drug label to reference. Clinicians who prescribe compounded CJC-1295 do so under their own clinical judgment and assume liability for patient outcomes [6]. The Endocrine Society's 2019 Clinical Practice Guideline on GH use in adults does not include CJC-1295 or other GH secretagogue peptides in its recommendations, citing insufficient evidence [18].

Monitoring protocols for patients on CJC-1295 typically follow the same parameters used for GH therapy: serum IGF-1 levels (targeting the age-adjusted upper half of the reference range), fasting glucose or HbA1c (given GH's diabetogenic effects), and lipid panels [18]. No validated CJC-1295-specific monitoring guideline exists.

Patients in the EU, Canada, and UK who encounter CJC-1295 through online vendors should be aware that purchasing an unauthorized medicine carries both legal risks and health risks, since products sold outside regulated pharmacy channels have no guarantee of identity, potency, or sterility [12]. The safest clinical alternative for adults with documented GH deficiency remains FDA-approved somatropin or, where available, tesamorelin for specific indications [4].

Clinicians considering CJC-1295 for a patient should document the clinical rationale, confirm that no approved GH product meets the patient's needs, use a verified 503A pharmacy with current accreditation, and monitor IGF-1 levels at 4-week intervals during initial titration [18].